Alterity registers open-label extension for ATH434 in French MSA patients
A new trial record offers continued ATH434 access to up to five patients who finished the ATH434-201 study, with dosing and safety monitoring specified.
Alterity Therapeutics registered one new study this week covering its investigational drug ATH434 in Multiple System Atrophy.
- ATH434-203 (NCT07729852), Phase 2, is a not yet recruiting open-label extension for patients who finished the earlier ATH434-201 trial in France. The study is designed to enroll up to 5 participants1, who will receive ATH434 at a dose of 75 mg twice daily, taken with food1. The record lists an estimated start of October 2026 and estimated completion in July 2029, with the primary objective of monitoring long-term safety, tolerability, and clinical response1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.